Abstract Library

#4557 miR-1290 and miR-320c regulate cell proliferation and predict patient prognosis in neuroendocrine carcinomas

Introduction: The biology of neuroendocrine carcinomas (NECs) remains largely unknown, limiting the use of biomarkers for patient stratification and therapy response prediction in clinical practice.

Conference:

Presenting Author: Liverani C

Authors: Liverani C, Sgolacchia F, Bongiovanni A, Calabrese C, Vanni S,

Keywords: biomarker, miRNAs, neuroendocrine carcinoma,

#4395 Mechanisms of drug resistance in neuroendocrine tumours: A basic research study

Introduction: Neuroendocrine tumours (NETs) often show resistance to chemotherapy and targeted therapies, leading to treatment failure. However, the molecular mechanisms underlying this resistance remain poorly understood.

Conference:

Presenting Author:

Authors: Xu L, Yu P, Chen J, Ye M, Xue B,

Keywords: Neuroendocrine tumour, drug resistance, mTOR, PI3K/AKT, tumour microenvironment, chemotherapy,

#4381 TOPK promotes tumorigenesis and metastasis of pancreatic neuroendocrine neoplasms by enhancing the MAPK signalling pathway

Introduction: T-LAK cell-originated protein kinase (TOPK) is highly expressed in pancreatic neuroendocrine neoplasms (pNENs) with liver metastasis and is associated with a poor prognosis.

Conference:

Presenting Author: Chen Q

Authors: Chen Q, Yuan M, Meng M, Ren S, Li G,

Keywords: TOPK, Pancreatic Neuroendocrine Neoplasm, MAPK signalling pathway, Invasion and metastasis, HI-TOPK-032,

#4316 Combination of sorafenib and everolimus regresses pancreatic neuroendocrine tumour significantly in vitro and vivo

Introduction: PNET is a rare group of highly heterogeneous tumours with neuroendocrine differentiation properties. Everolimus is the most promising drug for progressive well-differentiated pNETs. Sorafenib's anti-tumour activity may involve regulation of the mTOR pathway.

Conference:

Presenting Author: Zheng H

Authors: Zheng H,

Keywords: sorafenib, everolimus, pancreatic neuroendocrine tumour, mTOR,

#4146 Anticancer activity of Cabozantinib and Temozolomide in cell lines derived from lung carcinoid and pancreatic neuroendocrine tumors

Introduction: Limited therapeutic options are available for patients with advanced neuroendocrine neoplasms (NENs). Cabozantinib (CBZ), a tyrosine kinase inhibitor including c-MET pathway, and Temozolomide (TMZ), an alkylating agent enhancing the anti-angiogenic effect of CBZ, are emerging as promising treatments in NENs.

Conference:

Presenting Author:

Authors: Tornesello M, Starita N, Clemente O, Cerasuolo A, Bracigliano A,

Keywords: cabozantinib, temozolomide, neuroendocrine tumor, cell lines, in vitro study,